NuVasive — Q4 2017 Earnings Presentation
23 slides from NuVasive's earnings presentation, Feb 26, 2018
Slide 1: Q4/Full-Year 2017 Results Supplemental Presentation
Q4/Full-Year 2017 Results Supplemental Presentation to Earnings Press Release February 26, 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, leasehold related charges, integration related
Slide 4: Q4 2017 Financial Performance
Q4 2017 Financial Performance Strong international revenue growth of 34% on a constant currency basis Delivered GAAP operating profit margin of 11.0% and record non-GAAP operating profit margin of 18.2% Drove GAAP EPS of $0.46 and non-GAAP EPS of $0.56, growing at multiples of revenue despite softne
Slide 5: Full-Year 2017 Financial Performance
Full-Year 2017 Financial Performance Achieved $1 billion revenue milestone Delivered above-market revenue growth at 7.0% Drove international revenue growth of 20%+ throughout year Continued commitment to increased profitability drove operating margin expansion and non-GAAP earnings at 2x revenue gro
Slide 6: Q4 2017 Revenue Drivers
Q4 2017 Revenue Drivers Revenue (in millions) Q4 2017 Growth Rate Q4 2017 v. Q4 2016 Key Performance Factors U.S. Spinal Hardware Includes all Implants, Fixation & NuVasive Specialized Orthopedics (NSO) $148.4 (3.5%) Case volume growth of ~5% offset by a combination of pricing pressure and product m
Slide 7: Executed on Key Strategic Priorities in 2017
Executed on Key Strategic Priorities in 2017 Launched LessRay® System Expanded lateral procedural solutions Developed Advanced Materials Science™ portfolio Launched Reline® Small Stature and Reline® Trauma Launched expandable and 3D-printed cages Improved capital structure Authorized $100M share rep
Slide 8: Q4 & Full-Year 2017 P&L Performance
Q4 & Full-Year 2017 P&L Performance Non-GAAP Measures 4Q17 Actuals 4Q17 YoY Performance Factors FY17 Actuals FY17 YoY Performance Factors Gross Margin 72.4% 290 bps driven by slower than expected ramp up of our manufacturing facility and a slight uptick of pricing pressure 73.9% 270 bps driven by sl
Slide 9: Key Pillars Driving Multi-Faceted Growth
Key Pillars Driving Multi-Faceted Growth Disruptive Technology Commercial Success Globalization Develop the scale to grow international business to more than double revenue contribution. Compel hospitals and surgeons to use more NuVasive technology and services. Category leader innovating at a gener
Slide 10: Lateral Single-Position Surgery
Lateral Single-Position Surgery Lateral ALIF XLIF Crestline™ Lateral MAS® Fixation Comprehensive LATERAL PROCEDURAL SOLUTIONS from the upper thoracic to sacrum. XLIF®
Slide 11: Advanced Materials Science Portfolio
Proprietary Technology: Porous PEEK First-of-its kind porous architecture designed to promote superior bone in-growth, while maintaining the biomechanical and imaging properties of PEEK in general. Proprietary Technology: Modulus® Titanium Integrates endplate porosity with an optimized body lattice
Slide 12: Surgical Intelligence Platform
Surgical Intelligence Platform* INTEGRATED TO DELIVER PLANNING, SAFETY, IMAGING & NAVIGATION Radiation Reduction C-Arm technology integration High-quality, low-dose imaging Image-stitching capability Navigation Accurate instrument and implant tracking NUVA Procedural Integration Tracking in current
Slide 13: NuVasive Clinical Services
Serving ~100,000 U.S. cases annually – a national footprint 435+ Neurophysiologists and 35+ Physicians on staff Enhanced Surgical Monitoring & Remote Services A comprehensive spine solution Committed to Achieving Leadership in IONM Quality, Service and Technology #1 Service Leader for Intraoperative
Slide 14: Building Out NUVA International Platform
Strategy to more than double the International business over next five years at ~35% non-GAAP operating margins. International Revenue (Constant Currency*, In Millions) ~27% CAGR 14 * Constant currency based on 2017 rates. Building Out NUVA International Platform 4% INTERNATIONAL MARKET SHARE - SIGN
Slide 15: Delivering World-Class Self-Manufacturing
Delivering World-Class Self-Manufacturing $45 Million Investment 100 Pieces of Manufacturing Equipment 180,000 Square Feet Investment in self-manufacturing allows greater control and scalability to support long-term growth and improved margins Further align R&D and Product Development teams to optim
Slide 16: Strong History of Growth and Profitability
Strong History of Growth and Profitability Global Revenue (In Millions) Non-GAAP Operating Profit Margin $1,030 11.4% 15.4% 16.1% 16.6% ~520 Basis Points ~11% CAGR DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS $762 $811 $962
Slide 17: Driving Improved Adjusted EBITDA Margin
Driving Improved Adjusted EBITDA Margin DISCIPLINED APPROACH TO DRIVING MEANINGFUL PROFITABILITY IMPROVEMENTS Continued focus on improving the working capital profile and CapEx spending will drive incremental gains in the free cash profile of the company. FUTURE INITIATIVES Significantly reducing in
Slide 18: Impact of U.S. Tax Reform
Impact of U.S. Tax Reform U.S. TAX RATE REDUCED TO 21% EXPECTED TO BENEFIT EPS & FREE CASH FLOW NuVasive non-GAAP tax rate will drop to ~24% in 2018 and to ~20% and below in future periods. 2018 non-GAAP EPS and Free Cash Flow to benefit in excess of 10%. NuVasive plans to re-invest a portion of add
Slide 19: 2018 Full-Year Guidance
2018 Full-Year Guidance* $1,095M – $1,105M Full-Year Non-GAAP Operating Profit Margin Full-Year Revenue ~17.6% Full-Year Non-GAAP EPS $2.44 - $2.47 * NuVasive financial performance guidance as of February 26, 2018, inclusive of SafePassage (closed January 2018). ** Organic revenue growth excludes Sa
Slide 20: 2018 Guidance Assumptions
CONTRIBUTORS TO REVENUE GROWTH International revenue continues to grow 20%+ New product launches in 2H’17 ramp throughout the year In-sourced manufacturing efforts become significantly accretive in 2H’18 Biologics remains pressured for near-term U.S. spine procedural volumes relatively flat NUVASIVE
Slide 21: 2018 Full-Year Financial Performance Guidance
* NuVasive financial performance guidance as of February 26, 2018, inclusive of SafePassage (closed January 2018). 2018 Full-Year Financial Performance Guidance* Financial Measures FY18 Guidance Performance Drivers Revenue (as reported) $1,095M - $1,105M 6.4% to 7.3% growth Includes SafePassage cont
Slide 22: Steady Progress Against Investment Thesis
Steady Progress Against Investment Thesis RELENTLESS FOCUS ON DRIVING SHAREHOLDER VALUE International revenue growth 20%+; slower than expected U.S. growth, but still growing multiples of the market and taking share. Remain committed to annual 100 bps of non-GAAP op margin expansion; slower U.S. mar
Slide 23: Slide 23